DOW JONES27,081.36-879.44 -3.15%
S&P 5003,128.21-97.68 -3.03%
NASDAQ8,965.61-255.67 -2.77%

Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $148

Morgan Stanley maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $150 to $148.

Benzinga · 02/07/2020 14:29

Morgan Stanley maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $150 to $148.